{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:04:11Z","timestamp":1793714651622,"version":"4.6.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008105","name":"Catalunya La Pedrera Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008105","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.esmoop.2025.104543","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:36:41Z","timestamp":1744209401000},"page":"104543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study"],"prefix":"10.1016","volume":"10","author":[{"given":"A.","family":"Rodriguez-Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Garc\u00eda-Fructuoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Fratini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Segui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Potrony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sanfeliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Galvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Aceituno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Puig-Butille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Oriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Goberna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Sirenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ramon Y Cajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Balaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.104543_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104543_bib2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN Guidelines\u00ae Insights: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024","volume":"21","author":"Daly","year":"2023","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104543_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2023.9526","article-title":"Germline genetic testing after cancer diagnosis","volume":"330","author":"Kurian","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104543_bib4","first-page":"997","article-title":"Next-generation sequencing technology: current trends and advancements","volume":"12","author":"Satam","year":"2023","journal-title":"Biology (Basel)"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104543_bib5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2020.0229","article-title":"Prevalence of pathogenic variants in cancer susceptibility genes among women with postmenopausal breast cancer","volume":"323","author":"Kurian","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104543_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104543_bib7","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2022.4071","article-title":"Differences in cancer phenotypes among frequent CHEK2 variants and implications for clinical care-checking CHEK2","volume":"8","author":"Bychkovsky","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2025.104543_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.18632\/oncotarget.28604","article-title":"Genotype matters: personalized screening recommendations for germline CHEK2 variants","volume":"15","author":"Hernandez","year":"2024","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104543_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108324","article-title":"Timing of genetic testing in BRCA1\/2 and PALB2-associated breast cancer: preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy","volume":"50","author":"Apostolova","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104543_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10549-016-3792-1","article-title":"Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial","volume":"156","author":"Gonz\u00e1lez-Rivera","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104543_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000455999","article-title":"Germline mutations in triple-negative breast cancer","volume":"12","author":"Hahnen","year":"2017","journal-title":"Breast Care (Basel)"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104543_bib12","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/jnci\/djaa023","article-title":"The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort","volume":"112","author":"Hu","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104543_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","article-title":"Triple-negative breast cancer: promising prognostic biomarkers currently in development","volume":"21","author":"Sukumar","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104543_bib14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes \u2013 association analysis in more than 113,000 women","volume":"384","author":"Breast Cancer Association Consortium","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2025.104543_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1395970","article-title":"Germline rare variants in HER2-positive breast cancer predisposition: a systematic review and meta-analysis","volume":"14","author":"de Baumont","year":"2024","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104543_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.6744","article-title":"Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes","volume":"8","author":"Breast Cancer Association Consortium","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104543_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.surg.2023.09.015","article-title":"Assessment of the effect of the American Society of Breast Surgery guidelines on contralateral prophylactic mastectomy rates for unilateral breast cancer","volume":"175","author":"Steadman","year":"2024","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104543_bib18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology Guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104543_bib19","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.esmoop.2025.104543_bib20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104543_bib21","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104543_bib22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104543_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.annonc.2021.11.018","article-title":"Veliparib monotherapy following carboplatin\/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial","volume":"33","author":"Han","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104543_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10549-021-06292-7","article-title":"Phase II trial of veliparib and\u00a0temozolomide in metastatic breast cancer patients with and without BRCA1\/2 mutations","volume":"189","author":"Xu","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"10.1016\/j.esmoop.2025.104543_bib25","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104543_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104543_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104543_bib53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10549-025-07643-4","article-title":"Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice","volume":"210","author":"Potrony","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104543_bib28","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.104543_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.31427","article-title":"Universal genetic testing for newly diagnosed invasive breast cancer","volume":"7","author":"Rezoug","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104543_bib30","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","article-title":"Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis","volume":"136","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104543_bib31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10549-014-2980-0","article-title":"Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and\/or ovarian cancer syndrome testing","volume":"145","author":"Sharma","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.esmoop.2025.104543_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/humu.10260","article-title":"Analysis of BRCA1 and BRCA2 genes in Spanish breast\/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects","volume":"22","author":"Diez","year":"2003","journal-title":"Hum Mutat"},{"issue":"13","key":"10.1016\/j.esmoop.2025.104543_bib33","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2025.104543_bib34","doi-asserted-by":"crossref","first-page":"v94","DOI":"10.1093\/annonc\/mdx365.047","article-title":"Real-life study of BRCA genetic screening in metastatic breast cancer","volume":"28","author":"Meynard","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.104543_bib35","first-page":"PD1","article-title":"Abstract PD1-02: Cancer predisposition genes in metastatic breast cancer \u2013 association with metastatic pattern, prognosis, patient and tumor characteristics","volume":"78","author":"Fasching","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104543_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12885-020-07749-6","article-title":"The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis","volume":"21","author":"Moslemi","year":"2021","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2025.104543_bib37","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","article-title":"Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel","volume":"111","author":"Parsons","year":"2024","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104543_bib38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12920-022-01270-4","article-title":"How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?","volume":"15","author":"Kwong","year":"2022","journal-title":"BMC Med Genomics"},{"issue":"26","key":"10.1016\/j.esmoop.2025.104543_bib39","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","volume":"26","author":"Atchley","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104543_bib40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41523-021-00224-w","article-title":"Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants","volume":"7","author":"Lambertini","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104543_bib41","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00432-021-03696-2","article-title":"Germline and tumor BRCA1\/2 pathogenic variants in Chinese triple-negative breast carcinomas","volume":"147","author":"Ji","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104543_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13073-023-01177-4","article-title":"Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study","volume":"15","author":"Nacer","year":"2023","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104543_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12609-023-00478-2","article-title":"Genetic considerations in the locoregional management of breast cancer: a review of current evidence","volume":"15","author":"Bushara","year":"2023","journal-title":"Curr Breast Cancer Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104543_bib44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10549-022-06619-y","article-title":"Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy","volume":"194","author":"Dettwyler","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104543_bib45","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jmg-2022-108898","article-title":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2","volume":"60","author":"Hanson","year":"2023","journal-title":"J\u00a0Med Genet"},{"issue":"9","key":"10.1016\/j.esmoop.2025.104543_bib46","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41416-024-02827-z","article-title":"BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing","volume":"131","author":"Arun","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2025.104543_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4137\/BCBCR.S18715","article-title":"Hereditary breast cancer: clinical, pathological and molecular characteristics","volume":"8","author":"Larsen","year":"2014","journal-title":"Breast Cancer (Auckl)"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104543_bib48","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1007\/s00268-018-04897-6","article-title":"Global disparities in breast cancer genetics testing, counselling and management","volume":"43","author":"Yip","year":"2019","journal-title":"World J Surg"},{"issue":"9","key":"10.1016\/j.esmoop.2025.104543_bib49","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(22)00378-3","article-title":"Call for action: expanding global access to hereditary cancer genetic testing","volume":"23","author":"Bychkovsky","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104543_bib50","doi-asserted-by":"crossref","first-page":"898","DOI":"10.6004\/jnccn.2022.7022","article-title":"Impact of genetic counseling on patient-reported electronic cancer family history collection","volume":"20","author":"Vanderwall","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925004120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925004120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:38Z","timestamp":1762598678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925004120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2059702925004120"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104543","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104543"}}